The Central Drugs Laboratory, Karachi has achieved WHO prequalification—a significant milestone reflecting its growing capacity to ensure the quality, safety, and efficacy of medicines.
Recent Updates
- 59. Rapid Alert: Spurious/Falsified Drug Product i.e. Sandostatin LAR 20mg injection (Batch # 380531)November 17, 2026
- DRAP Launches Online Licensing and Registration System for Alternative Medicines and Health ProductsNovember 17, 2026
- 58. Rapid Alert: Spurious/Adulterated Gabica Capsule 300mgNovember 17, 2026
- S.R.O 2118(I)/2026 Fee for Alternative Medicines and Health Products (16.11.2026)November 17, 2026
- S.R.O.2117(I)/2026 (Alternative Medicines and Health Products Rules, 2026 (16.11.2026))November 17, 2026
- 57. Recall Alert: Drug product Declared as Substandard by Central Drugs Laboratories (CDL) KarachiNovember 16, 2026
- 56. Recall Alert: Drug products declared Substandard/Misbranded by Drug Testing laboratories PunjabNovember 16, 2026
- 55. Rapid Alert: Drug products declared Substandard/Adulterated by Drug Testing laboratories PunjabNovember 16, 2026
- Mandatory Compliance,Data Accuracy,System Verification for 2D barcoding and Serialization Requirments.November 16, 2026
- 54. Recall Alert: Drug products declared Substandard by Drug Testing laboratories PunjabNovember 16, 2026
- Show all updates
Chief Executive Officer
Dr. Obaidullah

E-Services
With the effective use of Information Technology, we have implemented a number of online services and continually working for more. Click here to browse available services.

Guidelines
Regulatory compliance is essential and indispensable in order to assure the safety, quality and efficacy of therapeutic goods. Guidance documents published by the Authority are meant to explain the current interpretation or policy for better understanding of the industry and

Quality Control Labs
For ensuring quality therapeutic goods, a network of quality control laboratories has been established. DRAP approved products and suspect therapeutic goods are tested for their quality in accordance with best international practices. To keep the citizens safe from substandard and

Health Professional Alerts
DRAP’s issues safety updates and alerts related to the therapeutic goods in order to ensure that healthcare professionals and other stakeholders have timely access to the relevant information on safety, quality and efficacy issues or benefit/risk evaluations of the drugs,

Medicine Availability
The Drug Regulatory Authority of Pakistan (DRAP) is committed to safeguard public health by ensuring the consistent availability of safe, efficacious, and quality medicines nationwide. Recognizing the critical impact of drug shortages, particularly of essential and lifesaving medicines, on patient
Pak-China Pharma & Healthcare B2B Collaboration
Investment Conference 2026. Investment facilitation, company profiling and B2B matchmaking portal. Facilitating technology transfer, joint ventures, and investment partnerships between Pakistani and Chinese pharmaceutical companies for a healthier tomorrow.
Do you know?
DRAP ensures that every drug, medical device or cosmetic, alternative medicine and health product must have a certain standard of quality and is safe and effective for your use. See in links below how it is done and what to do in case you find a suspect therapeutic good.




